In the context of a Lanham Act case, CRA assessed whether market performance for a hospital-based pharmaceutical product was affected by alleged improper statements by a competitor. CRA’s causality analysis included consideration of other economic factors that affected product sales, including assessment of market preparation, launch, commercialization, and promotional efforts used to support the product that was allegedly affected by improper marketing support.
Keler Marku joins CRA's Antitrust & Competition Practice
“We are pleased to welcome Keler back to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “Keler is an expert in...